Free Next (Working) Day Guaranteed Delivery on Orders Over £70! 🚚

Intex EQ-300

(1 customer review)

£ 36.00

DESCRIPTION:
Boldenone Undecylenate 300mg/ml
SKU: intexpharma-eq-300-boldenone-undecylenate Category:

Description

Boldenone Undecylenate is available in injectable form and is structurally similar to testosterone, with a slight modification to enhance its anabolic properties. It has a long ester attached to the hormone, which results in a prolonged half-life and a slower release into the body.

  1. Increased Protein Synthesis: Boldenone Undecylenate promotes protein synthesis, which is essential for muscle growth and repair. By enhancing the rate of protein synthesis, it supports the development of lean muscle mass and helps in achieving muscle gain goals.
  2. Nitrogen Retention: Boldenone Undecylenate aids in nitrogen retention in the muscles. Maintaining a positive nitrogen balance is crucial for muscle growth, as it enables a continuous state of anabolism. By preserving nitrogen, it supports muscle tissue growth and development.
  3. Enhanced Red Blood Cell Production: Boldenone Undecylenate has been reported to stimulate the production of red blood cells. Increased red blood cell count improves oxygen transportation to the muscles, enhancing endurance and performance during workouts. This can contribute to more productive training sessions, potentially leading to greater muscle gains.
  4. Appetite Stimulation: Boldenone Undecylenate has been known to increase appetite, which can be beneficial for individuals aiming to consume a higher calorie intake necessary for muscle gain. By promoting a healthy appetite, it supports the consumption of adequate nutrients needed for muscle growth.

1 review for Intex EQ-300

  1. Thomas H*****

    Very versatile compound, can be used for bulking, cutting and for a recomp
    Possibly the mildest sides ever from any anabolic and goes well with anything
    Always been a staple of mine and the vascularity is to die for

Add a review

Your email address will not be published. Required fields are marked *

To top